Thymosin Alpha-1: Test the Patient Outcome
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

Thymosin alpha-1 is studied for effects on immune function. Whether an immune signal changes is a different question from whether patients survive serious illness. The TESTS trial enrolled more than eleven hundred adults with sepsis across Chinese centres. Participants received thymosin alpha-1 or placebo alongside standard care. The analysis did not demonstrate a reduction in deaths within twenty-eight days. A published correction updated some calculations without turning this into a positive mortality finding. That result applies to this trial and setting. It neither proves all possible uses ineffective nor establishes a general immune-boosting benefit in healthy people.

END CARD
Educational draft. Not medical advice. Sources and limitations accompany this film.

SOURCES
[1] Wu et al. (2025): The efficacy and safety of thymosin alpha1 for sepsis (TESTS)
https://pmc.ncbi.nlm.nih.gov/articles/PMC11780596/
Primary multicentre randomized placebo-controlled phase 3 trial

[2] BMJ (30 May 2025): Correction to the TESTS trial
https://www.bmj.com/content/389/bmj.r1098.full.txt
Primary publisher correction

EVIDENCE LIMITATIONS
The trial concerns adults with sepsis, not immune enhancement in healthy people.
A nonsignificant primary outcome is not proof of equivalence or proof that every other indication is ineffective.
Use the corrected publication rather than stale hazard-ratio values.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
Thymosin Alpha-1: How Larger Trials Can Change an Immune-Therapy Story